NTI's mission is to become a global leader in SMD and revolutionize healthcare by empowering clinicians and researchers with the most sensitive, specific, and cost-effective diagnostic and analytical tools to detect disease at its earliest and most treatable stage. NTI’s goal is to commercialize automated, highly multiplexed protein- and nucleic acid-based diagnostic tests which can simultaneously detect and accurately quantify multiple biomarkers, pathogens, and/or genetic aberrations in very small patient samples.
NTI obtained an exclusive license for the patented Alternating Laser EXcitation (ALEX) technology, a SMD method based on multi-color fluorescence spectroscopy with vast commercial potential. NTI employs this new platform technology for development of analytical and diagnostic systems for various applications, consisting of spectroscopic analyzer instruments and reagent kits, and offers various services. The ALEX technology is a unique SMD technology for ultrasensitive, specific, and highly multiplexed barcoded detection and quantification of target molecules such as proteins, RNAs (including microRNAs), and DNAs in complex samples. Diagnostic application examples include tests for early cancer detection, acute myocardial infarction, osteoarthritis, traumatic brain injury, neurodegenerative diseases such as Alzheimers, Parkinsons, and other motosensory neuropathies, diabetes, asthma, infectious and autoimmune diseases, as well as bioterror agents.
The technology also provides information about molecular interactions and dynamics to investigate biological mechanisms and analyze conformations of biomolecules using single molecule fluorescence resonance energy transfer (smFRET). The high-resolution power for monitoring molecular dynamics and interactions allows viewing of biomolecular machineries in action, a unique breakthrough highly useful in multiple life sciences applications. It will also greatly aid structure-activity relationship (SAR) studies for drug discovery/lead optimization applications, opening new avenues for structure-guided rational drug design. In academia, ALEX has been used already extensively to study molecular dynamics of important complex biological processes such as gene transcription and biomolecular folding2-4.
The ALEX single molecule fluorescence spectroscopy instrumentation (“Analyzer”), advanced to four-colors (4c-ALEX) by NTI, is currently available as a research-grade prototype. NTI has secured several small business grants from the National Institutes of Health, published its proof-of-principle studies, and is expanding its IP position.
1. S. W. Yim et al., Clin Chem 58, 707 (2012)
2. A. N. Kapanidis et al., Science 314, 1144 (2006)
3. A. Chakraborty et al., Science, 337, 591 (2012)
4. X. Michalet et al.,Chemical reviews 106, 1785 (2006)